Pharmacological management of hypertension in pregnancy

Seminars in Perinatology

Volumn 38, Issue 8, 2014, Pages 487-495

  Easterling, Thomas R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Antihypertensive; Hypertension; IUGR; Preeclampsia; Pregnancy

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; CLONIDINE; FUROSEMIDE; HYDRALAZINE; LABETALOL; METHYLDOPA; METOPROLOL; NIFEDIPINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; VASODILATOR AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FETUS GROWTH; FETUS OUTCOME; HEART HEMODYNAMICS; HEART OUTPUT; HUMAN; MATERNAL HYPERTENSION; MEAN ARTERIAL PRESSURE; PREGNANCY OUTCOME; TREATMENT PLANNING; VASCULAR RESISTANCE; FEMALE; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; FEMALE; HUMANS; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; VASODILATOR AGENTS;

EID: 84918593753     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2014.08.016     Document Type: Review

References (29)

1. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42(6):1206-1252.
2. The Joint Commission. Sentinel Event Alert, Issue 44: "Preventing maternal death." ; 2010 Accessed 21.02.2014. http://www.jointcommission.org/assets/1/18/sea_44.pdf.
3. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013, 122(5):1122-1131.
4. Hebert M.F., Carr D.B., Anderson G.D., et al. Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol 2005, 45(1):25-33.
5. Zanger U.M., Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013, 138(1):103-141.
6. Wadelius M., Darj E., Frenne G., Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997, 62(4):400-407.
7. Högstedt S., Rane A. Plasma concentration-effect relationship of metoprolol during and after pregnancy. Eur J Clin Pharmacol 1993, 44(3):243-246.
8. Rogers R.C., Sibai B.M., Whybrew W.D. Labetalol pharmacokinetics in pregnancy-induced hypertension. Am J Obstet Gynecol 1990, 162(2):362-366.
9. Carvalho Teresa Maria J.P., Cavalli Ricardo de Carvalho, Cunha Sérgio P., et al. Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients. Eur J Clin Pharmacol 2011, 67(1):55-61.
10. Buchanan M.L., Easterling T.R., Carr D.B., et al. Clonidine pharmacokinetics in pregnancy. Drug Metab Dispos 2009, 37(4):702-705.
11. Claessens A.J., Risler L.J., Eyal S., Shen D.D., Easterling T.R., Hebert M.F. CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos 2010, 38(9):1393-1396.
12. Hebert M.F., Easterling T.R., Kirby B., et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther 2008, 84(2):248-253.
13. Prevost R.R., Akl S.A., Whybrew W.D., Sibai B.M. Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy 1992, 12(3):174-177.
14. Barton J.R., Prevost R.R., Wilson D.A., Whybrew W.D., Sibai B.M. Nifedipine pharmacokinetics and pharmacodynamics during the immediate postpartum period in patients with preeclampsia. Am J Obstet Gynecol 1991, 165(4 Pt 1):951-954.
15. Haas D.M., Quinney S.K., Clay J.M., et al. Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. Am J Perinatol 2013, 30(4):275-281.
16. Easterling T.R., Benedetti T.J., Schmucker B.C., Carlson K.L. Antihypertensive therapy in pregnancy directed by noninvasive hemodynamic monitoring. Am J Perinatol 1989, 6(1):86-89.
17. Rothberger S., Carr D., Brateng D., Hebert M., Easterling T.R. Pharmacodynamics of clonidine therapy in pregnancy: a heterogeneous maternal response impacts fetal growth. Am J Hypertens 2010, 23(11):1234-1240.
18. Carr D.B., Gavrila D., Brateng D., Easterling T.R. Maternal hemodynamic changes associated with furosemide treatment. Hypertens Pregnancy 2007, 26(2):173-178.
19. Easterling T.R., Benedetti T.J., Schmucker B.C., Millard S.P. Maternal hemodynamics in normal and preeclamptic pregnancies: a longitudinal study. Obstet Gynecol 1990, 76(6):1061-1069.
20. Bosio P.M., McKenna P.J., Conroy R., O[U+05F3]Herlihy C. Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol 1999, 94(6):978-984.
21. Orbach H., Matok I., Gorodischer R., et al. Hypertension and antihypertensive drugs in pregnancy and perinatal outcomes. Am J Obstet Gynecol 2013, 208(4). 301 (e1-e6).
22. Meidahl petersen K., Jimenez-solem E., Andersen J.T., et al. β-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open 2012, 2:4.
23. Lydakis C., Lip G.Y., Beevers M., Beevers D.G. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens 1999, 12(6):541-547.
24. Abalos E., Duley L., Steyn D.W. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2014, 2:CD002252. http://dx.doi.org/10.1002/14651858.CD002252.pub2.
25. Carr D.B., Tran L.T., Brateng D.A., et al. Hemodynamically-directed atenolol therapy is associated with a blunted rise in maternal sFLT-1 levels during pregnancy. Hypertens Pregnancy 2009, 28(1):42-55.
26. Easterling T.R., Benedetti T.J., Carlson K.C., Brateng D.A., Wilson J., Schmucker B.S. The effect of maternal hemodynamics on fetal growth in hypertensive pregnancies. Am J Obstet Gynecol 1991, 165(4 Pt 1):902-906.
27. Von dadelszen P., Ornstein M.P., Bull S.B., Logan A.G., Koren G., Magee L.A. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000, 355(9198):87-92.
28. Easterling T.R., Brateng D., Schmucker B., Brown Z., Millard S.P. Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol 1999, 93(5 Pt 1):725-733.
29. Easterling T.R., Carr D.B., Brateng D., Diederichs C., Schmucker B. Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol 2001, 98(3):427-433.